Benzinga | Jul 29, 2020 06:59AM EDT

Guggenheim Initiates Coverage On Protara Therapeutics with Buy Rating, Announces Price Target of $50

Guggenheim initiates coverage on Protara Therapeutics (NASDAQ:TARA) with a Buy rating and announces Price Target of $50.